论文部分内容阅读
本研究通过测定血清阿霉素浓度,分析了原发性肝癌阿霉素肝动脉灌注(A 组)、阿霉素碘油乳化后栓塞(B 组)及阿霉素微囊栓塞化疗(C 组)后药动学变化及其临床意义。A 组药动学变化与静脉给药相似,但峰值浓度高。B 组峰浓度低,半衰期延长,显示缓释和降低血浓度的作用。C 组峰浓度不明显,表现为长时、稳定的释放,血浓度低,具有保持局部长时间高浓度作用。结果揭示了肝癌介入治疗不同给药方法疗效差异的药动学依据。
In this study, the serum adriamycin concentration was measured to analyze the hepatic arterial infusion of doxorubicin (group A), doxorubicin emulsification after embolization of doxorubicin (group B), and doxorubicin microcapsule embolization chemotherapy (group C). ) Post pharmacokinetic changes and its clinical significance. Changes in pharmacokinetics of group A were similar to those of intravenous administration, but peak concentrations were high. In group B, the peak concentration was low and the half-life was prolonged, showing the effect of sustained release and lowering blood concentration. The peak concentration in group C was not obvious, showing a long-term, stable release, low blood concentration, and it had the effect of maintaining local high concentration for a long time. The results revealed the pharmacokinetic basis for the difference in efficacy of different methods of interventional treatment of liver cancer.